INNO (INNO) News
Follow INNO (INNO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA
HERZLIYA, Israel and CALGARY, Alberta, Sept. 29, 2026 // -- Innocan Pharma Corporation (CSE:INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), through B.I. Sky Global Ltd., its consumer wellness subsidiary, is pleased to
GEOPOLITICS | Sep 29, 2026, 08:00 PM UTC
L
Innocan Pharma Corporation (INNO) Raises C$0.46M in Unit Private Placement
Innocan Pharma closed a private placement of 247,314 units at C$1.87 for gross proceeds of C$462,477, with each unit including a share and a 3-year warrant at C$2.50. Proceeds are for working capital and general corporat
NEWS | Sep 23, 2026, 08:02 PM UTC
H
Innocan Pharma Announces First Tranche Closing of Private Placement of Units
HERZLIYA, Israel and CALGARY, Alberta, Sept. 23, 2026 // -- Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTC:INNPF) (the "Company" or "Innocan") is pleased to announce that, further to its press release of September
GEOPOLITICS | Sep 23, 2026, 08:01 PM UTC
M
Innocan Pharma intends to complete private placement of up to 535,000 units
Innocan Pharma said it intends to complete a private placement of up to 535,000 units at C$1.87 per unit.
MNA | Sep 09, 2026, 08:37 PM UTC
M
INNO revenue down 25% YoY; gross margin at 90.8%
INNO reported revenue down 25% year-over-year. Gross margin stayed strong at 90.8%.
EQUITY | Aug 31, 2026, 08:23 PM UTC
M
Innocan Pharma posts Q2 FY2026 revenue of US$5.25M (CAD 7.3M)
Innocan Pharma reported second quarter fiscal year 2026 revenue of US$5.25M (CAD 7.3M).
EQUITY | Aug 31, 2026, 08:01 PM UTC